PCV81 Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective

Simple item page
dc.contributor.authorKostyuk, A
dc.contributor.authorAlmadiyeva, A
dc.contributor.authorNurgozhin, T
dc.creatorA, Kostyuk
dc.date.accessioned2017-12-20T08:55:06Z
dc.date.available2017-12-20T08:55:06Z
dc.date.issued2017-10-01
dc.description.abstractApixaban, dabigatran, and rivaroxaban are 3 novel oral anticoagulants (NOACs) currently approved for stroke prevention in patients with atrial fibrillation (AF). Although warfarin remains the standard of care in Kazakhstan.The objective of this study was to evaluate the cost-effectiveness of apixaban against other NOACs and warfarin from the considering costs and savings for public payers perspective in Kazakhstanen_US
dc.identifierDOI:10.1016/j.jval.2017.08.1227
dc.identifier.citationA Kostyuk, A Almadiyeva, T Nurgozhin, PCV81 - Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspective, In Value in Health, Volume 20, Issue 9, 2017, Page A615en_US
dc.identifier.issn10983015
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1098301517315619
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/2963
dc.language.isoenen_US
dc.publisherValue in Healthen_US
dc.relation.ispartofValue in Health
dc.rights.licenseCopyright © 2017 Published by Elsevier Inc.
dc.titlePCV81 Cost-Effectiveness of Apixaban For Stroke Prevention In Atrial Fibrillation: An Kazakhstan Perspectiveen_US
dc.typeArticleen_US
elsevier.aggregationtypeJournal
elsevier.coverdate2017-10-01
elsevier.coverdisplaydateOctober–November 2017
elsevier.identifier.doi10.1016/j.jval.2017.08.1227
elsevier.identifier.eid1-s2.0-S1098301517315619
elsevier.identifier.piiS1098-3015(17)31561-9
elsevier.issue.identifier9
elsevier.openaccess0
elsevier.openaccessarticlefalse
elsevier.openarchivearticlefalse
elsevier.startingpageA615
elsevier.volume20
workflow.import.sourcescience

Files

Collections

Articles